Back to top
more

CareDx (CDNA)

(Delayed Data from NSDQ)

$29.88 USD

29.88
477,483

+0.62 (2.12%)

Updated Sep 19, 2024 04:00 PM ET

After-Market: $29.89 +0.01 (0.03%) 6:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (148 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Select Medical Rises 50.2% YTD: Take Profits or Bet on More Gains?

by Zacks Equity Research

SEM's profitability is being impacted by rising costs and expenses.

Teladoc Stock Rises 12% as Jefferies Boosts Price Target on BetterHelp

by Zacks Equity Research

TDOC's stock benefits from improving web traffic in its BetterHelp platform.

Community Health's Arm Northwest Urgent Buys 10 Arizona Facilities

by Zacks Equity Research

CYH expects the acquisition from Carbon Health to be completed in the fourth quarter of 2024.

Pediatrix Medical Up 45.8% in 3 Months: Is it Too Late to Jump In?

by Zacks Equity Research

MD remains one of the best-positioned pediatric service providers with favorable valuation to achieve margin improvement.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: CareDx, Fair Isaac, 3M in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and CareDx (CDNA) have performed compared to their sector so far this year.

CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

CareDx (CDNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

CareDx (CDNA) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

CareDx (CDNA) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

CareDx (CDNA) delivered earnings and revenue surprises of 292.31% and 37.32%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Biodesix (BDSX) delivered earnings and revenue surprises of 6.67% and 5.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?

by Zacks Equity Research

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

How CareDx (CDNA) Stock Stands Out in a Strong Industry

by Zacks Equity Research

CareDx (CDNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

CareDx (CDNA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Unlocking Q4 Potential of CareDx (CDNA): Exploring Wall Street Estimates for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

How Much Upside is Left in CareDx (CDNA)? Wall Street Analysts Think 26.72%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can CareDx (CDNA) Climb 29.79% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for CareDx (CDNA) points to a 29.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

CareDx (CDNA) Surges 16.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CareDx (CDNA) delivered earnings and revenue surprises of 57.14% and 24.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Viatris (VTRS) delivered earnings and revenue surprises of 5.63% and 0.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Soars 20.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CareDx (CDNA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

CareDx (CDNA) delivered earnings and revenue surprises of -57.14% and 3.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?